Table 3.

Multivariate analysis of risk factors for NRM and survival in 1117 pediatric patients with cGVHD

	NRM			Survival
	Relative risk	95% CI	P	Relative risk	95% CI	P
Age (baseline: 0-9 y)
10-19 y	NS	—	—	1.32	1.09; 1.60	.005
KPS/L (baseline: 80-100)	—	—	< .001	—	—	< .001
< 80	3.01	2.29; 3.96	< .001	1.89	1.52; 2.34	< .001
Unknown	1.64	1.12; 2.43	.015	1.34	1.00; 1.78	.05
Platelets, × 109/L (baseline: ≥ 100)	—	—	< .001	—	—	< .001
< 100	2.32	1.76; 3.07	< .001	1.63	1.32; 2.01	< .001
Unknown	1.73	1.18; 2.52	.005	1.33	0.99; 1.78	.06
Donor (baseline: HLA-identical siblings)	—	—	< .001	—	—	.003
Other related	1.67	0.96; 2.96	.07	1.68	1.13; 2.52	.011
HLA well-matched URD	1.25	0.80; 1.96	.33	1.40	1.02; 1.94	.04
Partially matched URD	1.94	1.28; 2.94	.002	1.69	1.23; 2.31	.001
Mismatched URD	2.31	1.49; 3.59	< .001	1.75	1.27; 2.42	< .001
No data	1.22	0.60; 2.13	.71	1.02	0.64; 1.62	.94
Disease state (baseline: early)	—	—	.005	—	—	< .001
Intermediate	0.65	0.50; 0.85	.07	0.96	0.78; 1.18	.70
Advanced	0.92	0.63; 1.35	.68	1.56	1.19; 2.04	.001
Graft (baseline: BM)	—	—	.002	—	—	—
PB	1.76	1.28; 2.41	< .001	NS	—	—
Cord blood	1.07	0.67; 1.70	.78	NS	—	—

NS indicates not significant; and —, not applicable.